Roubaix Capital LLC trimmed its position in Shoulder Innovations, Inc. (NYSE:SI – Free Report) by 9.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 229,944 shares of the company’s stock after selling 25,344 shares during the period. Roubaix Capital LLC’s holdings in Shoulder Innovations were worth $4,346,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of Shoulder Innovations by 7,046.3% during the 1st quarter. Royal Bank of Canada now owns 53,883 shares of the company’s stock valued at $783,000 after purchasing an additional 53,129 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Shoulder Innovations during the 2nd quarter valued at about $896,000. KCM Capital Inc bought a new position in shares of Shoulder Innovations in the 1st quarter worth approximately $509,000. CenterBook Partners LP bought a new position in shares of Shoulder Innovations in the 3rd quarter worth approximately $784,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Shoulder Innovations in the 2nd quarter worth approximately $35,000.
Wall Street Analyst Weigh In
SI has been the topic of a number of research reports. UBS Group raised their price objective on shares of Shoulder Innovations from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Shoulder Innovations in a research report on Friday, October 30th. Finally, BTIG Research lifted their price target on shares of Shoulder Innovations from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.75.
Check Out Our Latest Report on Shoulder Innovations
Insider Transactions at Shoulder Innovations
In related news, CEO Robert Ball sold 10,175 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.45, for a total value of $187,728.75. Following the completion of the sale, the chief executive officer directly owned 380,824 shares of the company’s stock, valued at approximately $7,026,202.80. This represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Healthcare Holding B.V. Gilde sold 20,516 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $22.61, for a total transaction of $463,866.76. Following the completion of the sale, the insider directly owned 2,187,791 shares of the company’s stock, valued at $49,465,954.51. This represents a 0.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 36,468 shares of company stock worth $782,169. Insiders own 29.00% of the company’s stock.
Shoulder Innovations Price Performance
NYSE SI opened at $20.52 on Wednesday. The business’s fifty day moving average is $19.08 and its 200 day moving average is $17.40. Shoulder Innovations, Inc. has a fifty-two week low of $12.00 and a fifty-two week high of $24.59. The company has a current ratio of 10.68, a quick ratio of 8.69 and a debt-to-equity ratio of 0.13.
Shoulder Innovations (NYSE:SI – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.15. The business had revenue of $16.19 million during the quarter. Shoulder Innovations had a negative return on equity of 25.37% and a negative net margin of 51.72%. Research analysts forecast that Shoulder Innovations, Inc. will post -1.70 EPS for the current fiscal year.
Shoulder Innovations Company Profile
Shoulder Innovations, Inc. is a medical technology company focused on developing and commercializing products for shoulder replacement surgery. Its offerings are designed for orthopedic surgeons treating patients with shoulder conditions that may require joint replacement. The company’s product portfolio includes shoulder implant systems such as its InSet glenoid and Catalyst reverse shoulder technologies, along with related surgical instruments. These products support different approaches to shoulder arthroplasty, including procedures that replace or reconstruct parts of the shoulder joint.
Featured Stories
- Five stocks we like better than Shoulder Innovations
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding SI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shoulder Innovations, Inc. (NYSE:SI – Free Report).
Receive News & Ratings for Shoulder Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shoulder Innovations and related companies with MarketBeat.com's FREE daily email newsletter.
